MET 14 Deletion in Sarcomatoid Non-Small-Cell Lung Cancer Detected by Next- Generation Sequencing and Successfully Treated with a MET Inhibitor  Carrie.

Slides:



Advertisements
Similar presentations
Lung Adenocarcinoma with Ipsilateral Breast Metastasis: A Simple Coincidence? Hsu-Ching Huang, MD, Jen-Fan Hang, MD, Mei-Han Wu, MD, Teh-Ying Chou, MD,
Advertisements

Massive Bronchogenic Cyst Joseph B. Levin, BA, Chi Wan Koo, MD, Jessica S. Donington, MD Journal of Thoracic Oncology Volume 5, Issue 11, Pages
Primary Small Cell Carcinoma of the Esophagus Jima Lv, MD, Jun Liang, MD, Jinwan Wang, MD, Luhua Wang, MD, Jie He, MD, Zefen Xiao, MD, Weibo Yin, MD Journal.
Development of Renal Cysts after Crizotinib Treatment in Advanced ALK-Positive Non– Small-Cell Lung Cancer Yen-Ting Lin, MD, Yu-Fen Wang, MD, James Chih-Hsin.
A Hole in the Heart Journal of Thoracic Oncology
Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non– Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor.
Carcinoma NOS is a Common Histologic Diagnosis and is Increasing in Proportion Among Non-small Cell Lung Cancer Histologies  Sai-Hong Ignatius Ou, MD,
Two Classic Lyrics Joined by a Contemporary Tune—Environmental Pro-Carcinogen Exposure and Genetic Susceptibility in Lung Cancer Risk  Ping Yang, MD,
Successful Osimertinib Rechallenge in a Patient with T790M-Mutant Non–Small Cell Lung Cancer after Osimertinib-Induced Interstitial Lung Disease  Eisaku.
Next Generation Sequencing Uncovers Potential Genetic Driver Mutations of Malignant Pulmonary Granular Cell Tumor  Song Xu, Qingchun Zhao, Sen Wei, Yi.
Disparities in Treatment of Patients with Inoperable Stage I Non–Small Cell Lung Cancer: A Population-Based Analysis  Matthew Koshy, MD, Renuka Malik,
SC17.02 Lung Cancer in China: Challenges and Perspectives
ALK FISH and IHC: You Cannot Have One without the Other
Michael C. Roach, MD, Gregory M. M. Videtic, MD, CM, FRCPC, Jeffrey D
The BIM Deletion Polymorphism and its Clinical Implication in Patients with EGFR- Mutant Non–Small-Cell Lung Cancer Treated with EGFR Tyrosine Kinase Inhibitors 
Durable Response to Tyrosine Kinase Inhibitor Therapy in a Lung Cancer Patient Harboring Epidermal Growth Factor Receptor Tandem Kinase Domain Duplication 
MET Mutation Associated with Responsiveness to Crizotinib
MET-Mutated NSCLC with Major Response to Crizotinib
NA  Journal of Thoracic Oncology 
Electronic Updates for JTO Readers
The International Association for the Study of Lung Cancer International Staging Project on Lung Cancer  Peter Goldstraw, MB, FRCS, John J. Crowley, PhD 
A Long-Term Spinal Intramedullary Response to Ceritinib in ALK Rearranged Non– Small-Cell Lung Cancer  Josette Biya, MD, Caroline Caramella, MD, Colin.
Frank Detterbeck, MD  Journal of Thoracic Oncology 
Ziad Thotathil, MD, FRCR, Jeremy Long, FRACP 
Central versus Peripheral Tumor Location: Influence on Survival, Local Control, and Toxicity Following Stereotactic Body Radiotherapy for Primary Non–Small-Cell.
The Influence of the Evolution of First-Line Chemotherapy on Steadily Improving Survival in Advanced Non-Small-Cell Lung Cancer Clinical Trials  Krista.
A Severe Photosensitivity Dermatitis Caused by Crizotinib
LKB1 Regulated Pathways in Lung Cancer Invasion and Metastasis
Effective Treatment with Icotinib in Primary Adenoid Cystic Carcinoma of the Lung with Liver Metastasis  Zhengbo Song, MD, Wei Wu, MD, Yiping Zhang, MD 
Intratumoral Lymphatic Vessel Involvement is an Invasive Indicator of Completely Resected Pathologic Stage I Non-small Cell Lung Cancer  Masahiko Harada,
Jeffrey Bradley, MD, Issam El Naqa, PhD  Journal of Thoracic Oncology 
Crizotinib Improves Osteoarthritis Symptoms in a ROS1-Fusion Advanced Non–Small Cell Lung Cancer Patient  Jordi Remon, MD, Anas Gazzah, MD, Benjamin Besse,
Socioeconomic Status Is Associated with Depressive Severity Among Patients with Advanced Non–Small-Cell Lung Cancer: Treatment Setting and Minority Status.
Strategies to Improve Outcomes of Patients with EGFR-Mutant Non–Small Cell Lung Cancer: Review of the Literature  Caicun Zhou, MD, PhD, Luan Di Yao, MD 
A Hole in the Heart Journal of Thoracic Oncology
Coexistence of Tyrosine Kinase Inhibitor-Sensitizing and Resistant EGFR Mutations in an Untreated Lung Adenocarcinoma Patient and Response to Erlotinib 
Aya Fukuizumi, MD  Journal of Thoracic Oncology 
A Different Method in Diagnosis of Multiple Primary Lung Cancer
Elizabeth Cathcart-Rake, MD, Ariel Lopez-Chavez, MD, MS 
Positron Emission Tomography 18F-Fluorodeoxyglucose Uptake and Prognosis in Patients with Surgically Treated, Stage I Non-small Cell Lung Cancer: A Systematic.
Vamsidhar Velcheti, MD  Journal of Thoracic Oncology 
Combination Treatment Using an EGFR Tyrosine Kinase Inhibitor plus Platinum-Based Chemotherapy for a Patient with Transformed Small Cell Carcinoma and.
Mitotic Inhibitors Journal of Thoracic Oncology
Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non– Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor.
Aglaya G. Iyevleva, MD, PhD  Journal of Thoracic Oncology 
Mirror Mirror on the Wall, Who Is the Fairest of Them All
EGFR delE709_T710insD: A Rare but Potentially EGFR Inhibitor Responsive Mutation in Non–Small-Cell Lung Cancer  Allison Ackerman, MD, Michael A. Goldstein,
Trends in Stage Distribution for Patients with Non-small Cell Lung Cancer: A National Cancer Database Survey  Daniel Morgensztern, MD, Shean Huey Ng,
Phase I Study of Lenalidomide in Solid Tumors
T4 or MI? Journal of Thoracic Oncology Volume 6, Issue 3, (March 2011)
Jie Huang, Juan Peng, Linlang Guo, MD, PhD 
Recursive Partitioning Analysis Groups II–III Brain Metastases of Non-small Cell Lung Cancer: A Phase II Randomized Study Comparing Two Concurrent Chemoradiotherapy.
Manoj P. Menon, MD, MPH, Keith D. Eaton, MD, PhD 
In This Issue Journal of Thoracic Oncology
Genetic Changes in Squamous Cell Lung Cancer: A Review
Ethnic Differences in Survival Outcome in Patients with Advanced Stage Non-small Cell Lung Cancer: Results of a Meta-Analysis of Randomized Controlled.
Ethnic Differences in the Management of Lung Cancer in New Zealand
European Lung Cancer Conference (ELCC) 2016 Organisation
Trichomegaly of the Eyelashes After Treatment with Erlotinib in Non-small Cell Lung Cancer  Judith Elizabeth Carser, MB, BCh, MRCR, Yvonne Jane Summers,
Impressive Response to Tyrosine Kinase Inhibitors in a Patient with Respiratory Failure for EGFR-Mutated Metastatic Lung Cancer  Elena Bolzacchini, MD,
S-1 Treatment for Chemorefractory Thymic Carcinoma
IASLC 6th Latin American Conference on Lung Cancer
Christina S. Baik, MD, MPH, Marc C. Chamberlain, MD, Laura Q. Chow, MD 
Tumor Lysis Syndrome in Limited-Stage Small-Cell Lung Cancer
APLCC POSTER SESSION 2 - WEDNESDAY, NOVEMBER 28
David Garfield, MD  Journal of Thoracic Oncology 
Two Rare Exon 21 EGFR Mutations in Patients Treated with Gefitinib
A Review of First-Line Treatment for Small-cell Lung Cancer
Robert Comis, MD, The Passing of a “Lung Man”
Ana Luque, MD, Edurne Arriola, MD, PhD  Journal of Thoracic Oncology 
Presentation transcript:

MET 14 Deletion in Sarcomatoid Non-Small-Cell Lung Cancer Detected by Next- Generation Sequencing and Successfully Treated with a MET Inhibitor  Carrie Lee, MD, Dimitry Usenko, MD, Garrett M. Frampton, PhD, Caitlin McMahon, Siraj M. Ali, MD, PhD, Jared Weiss, MD  Journal of Thoracic Oncology  Volume 10, Issue 12, Pages e113-e114 (December 2015) DOI: 10.1097/JTO.0000000000000645 Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Figure 1 Pre- and post treatment CT scans. Journal of Thoracic Oncology 2015 10, e113-e114DOI: (10.1097/JTO.0000000000000645) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions